Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403109![]() (US10329303, Example 12) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 75 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403244![]() (US10329303, Example 43) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 500 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403225![]() (US10329303, Example 24) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 1 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403229![]() (US10329303, Example 28) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 40 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403240![]() (US10329303, Example 39) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 90 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403243![]() (US10329303, Example 42) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403251![]() (US10329303, Example 50) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM402975![]() (US10329303, Example 4) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 200 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403093![]() (US10329303, Example 9) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403094![]() (US10329303, Example 10) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 90 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403155![]() (US10329303, Example 16) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 220 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403188![]() (US10329303, Example 21) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403224![]() (US10329303, Example 23) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403226![]() (US10329303, Example 25) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 300 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403239![]() (US10329303, Example 38) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403095![]() (US10329303, Example 11) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 25 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403234![]() (US10329303, Example 33) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 70 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403245![]() (US10329303, Example 44) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 200 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403246![]() (US10329303, Example 45) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403252![]() (US10329303, Example 51) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403182![]() (US10329303, Example 19) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 70 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403184![]() (US10329303, Example 20) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403231![]() (US10329303, Example 30) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 600 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403237![]() (US10329303, Example 36) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 100 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403248![]() (US10329303, Example 47) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM402882![]() (US10329303, Example 2) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 100 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM402974![]() (US10329303, Example 3) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403040![]() (US10329303, Example 6) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403118![]() (US10329303, Example 14) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403228![]() (US10329303, Example 27) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 80 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403233![]() (US10329303, Example 32) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 900 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403238![]() (US10329303, Example 37) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 100 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403241![]() (US10329303, Example 40) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 50 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403242![]() (US10329303, Example 41) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 800 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403247![]() (US10329303, Example 46) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403249![]() (US10329303, Example 48) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403059![]() (US10329303, Example 8) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 34 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403181![]() (US10329303, Example 18) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 900 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403230![]() (US10329303, Example 29) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 80 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403253![]() (US10329303, Example 52) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM402876![]() (US10329303, Example 1) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403041![]() (US10329303, Example 7) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403142![]() (US10329303, Example 15) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403158![]() (US10329303, Example 17) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 100 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403235![]() (US10329303, Example 34) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 1 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403250![]() (US10329303, Example 49) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403025![]() (US10329303, Example 5) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 160 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403218![]() (US10329303, Example 22) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | <20 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403227![]() (US10329303, Example 26) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 90 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403232![]() (US10329303, Example 31) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 100 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403236![]() (US10329303, Example 35) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 80 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Malignant T-cell-amplified sequence 1 (Homo sapiens (human)) | BDBM403111![]() (US10329303, Example 13) | PDB UniProtKB/SwissProt GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 50 | n/a | n/a | n/a | n/a |
The Scripps Research Institute US Patent | Assay Description pecific Examples 1-52 of compounds of the invention, with estimated EC50 values determined using an MTT assay for 4-day viability of Raji (Burkitt... | US Patent US10329303 (2019) BindingDB Entry DOI: 10.7270/Q2B27XM9 | |||||||||||
More data for this Ligand-Target Pair |